ReviewGut microbes2025
A review of engraftment assessments following fecal microbiota transplant.
Abstract readReview
In one paragraph
Review in Gut microbes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 2 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Fecal microbiota transplantation from psychiatric patients to mice - systematic review of methodologies and a call for standardization.Translational psychiatry · 2026Pooled it
- Global research trends in gut microbiota and cellular senescence: a bibliometric and visual analysis from 2015 to 2025.Frontiers in microbiology · 2025Pooled it
- Fecal microbiota transplantation plus pembrolizumab and axitinib in metastatic renal cell carcinoma: the randomized phase 2 TACITO trial.Nature medicine · 2026Trial
- Review
- Antibiotic-Driven Gut Microbiome Dysbiosis: Resistome Dynamics, Metabolic Disruption, and Paths to Restoration.Antibiotics (Basel, Switzerland) · 2026Review
- Fecal microbiota transplantation in chronic liver disease: Current and future state of the art.Hepatology communications · 2026Review
- Decoding the power of the microbiome in human health.Frontiers in cellular and infection microbiology · 2026Review
- The role of the gut-lung axis in persistent inflammation and disease progression in chronic obstructive pulmonary disease: mechanistic evidence and therapeutic implications.Frontiers in immunology · 2026Review
- Insights into the mechanism of intestinal flora imbalance and immune disorder in co-morbidity of pneumonia and diarrhea in children.Frontiers in pediatrics · 2026Review
- Fecal microbiota transplantation: from empirical remedy to precision medicine.Frontiers in microbiomes · 2026Review
- The gut microbiota-immune-brain axis in post-traumatic stress disorder: mechanistic integration and translational prospects.Frontiers in immunology · 2026Review
- Exploring the intricate link between gut microbiota dysbiosis and the aging process: implications for age-related diseases.Gut pathogens · 2025Review
- CRISPR-engineered microbiome: living therapeutics revolutionize blood cancer immunotherapy.NPJ biofilms and microbiomes · 2025Review
- The challenges and opportunities in the expanding horizons of microbiota transplant therapies.Gut microbes · 2025Article
- Article
- Assessing microbiome engraftment extent following fecal microbiota transplant with q2-fmt.PLoS computational biology · 2025Article
- Fecal microbiota transplantation as salvage therapy for disseminated strongyloidiasis in an immunosuppressed patient: a case report.Frontiers in immunology · 2025Article
- Advances in Nanomedicine-Mediated Modulation of the Microbiome for Cancer Therapy.International journal of nanomedicine · 2025Review
- Editorial: Fecal Microbiota Transplants: challenges in translating microbiome research to clinical applications.Frontiers in microbiology · 2025Article
Corrections and comments
- Update of
Authors and funding
12 authors.
Chloe HermanPathogen and Microbiome Institute, Northern Arizona University, Flagstaff, AZ, USA.
Bridget M BarkerPathogen and Microbiome Institute, Northern Arizona University, Flagstaff, AZ, USA.
Thais F BartelliDepartment of Genetics, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Vidhi ChandraDepartment of Genetics, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Rosa Krajmalnik-BrownBiodesign Center for Health Through Microbiomes, Arizona State University, Tempe, AZ, USA.ORCID 0000-0001-6064-3524
Mary JewellIndependent Author, Salt Lake City, UT, USA.
Le LiDepartment of Genetics, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Chen LiaoProgram for Computational and Systems Biology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
Florencia McAllisterDepartment of Genetics, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Khemlal NirmalkarBiodesign Center for Health Through Microbiomes, Arizona State University, Tempe, AZ, USA.
Joao B XavierProgram for Computational and Systems Biology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
J Gregory CaporasoPathogen and Microbiome Institute, Northern Arizona University, Flagstaff, AZ, USA.
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4MAdvanced Development of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)U24CA248454 · NCI · NORTHERN ARIZONA UNIVERSITY · PI CAPORASO, JAMES GREGORY · 2020 to 2024
$3.7MUnraveling the ecology of intestinal fungal expansion in immunocompromised patients through computational modeling and machine learningR00AI175599 · NIAID · DARTMOUTH COLLEGE · PI LIAO, CHEN · 2025 to 2025
$247kUnraveling the ecology of intestinal fungal expansion in immunocompromised patients through computational modeling and machine learningK99AI175599 · NIAID · SLOAN-KETTERING INST CAN RESEARCH · PI LIAO, CHEN · 2024 to 2025
$170kNCI NIH HHS P30 CA008748NCI NIH HHS U24 CA248454NIAID NIH HHS K99 AI175599NIAID NIH HHS R00 AI175599
Abstract
Fecal Microbiota Transplant (FMT) is a treatment for recurrent
Indexed as
Clostridium InfectionsFecal Microbiota TransplantationGastrointestinal MicrobiomeAnimalsBacteriaClostridioides difficileFecesHumansbacteriotherapybioinformaticsengraftmentFecal microbiota transplantintestinal microbiota transplantmicrobiomestool transplant
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.